Zydus Lifesciences forms JV with Sunshine Healthcare Lanka for Sri Lanka manufacturing

1 min read     Updated on 27 Jun 2026, 09:24 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Zydus Lifesciences has formed a 50:50 joint venture with Sunshine Healthcare Lanka to establish Zydus Sunshine Lifesciences (Private) Limited, a pharmaceutical manufacturing entity in Sri Lanka. The company will invest up to USD 5 million to subscribe to 50% of the equity, with a total project commitment of over USD 20 million. The facility, located in the Horana Export Processing Zone, aims to reduce import dependence and improve access to high-quality medicines.

powered bylight_fuzz_icon
43986967

*this image is generated using AI for illustrative purposes only.

Zydus Lifesciences has entered into a joint venture with Sunshine Healthcare Lanka Limited to establish a pharmaceutical manufacturing facility in Sri Lanka, aiming to strengthen local production and reduce import dependence. The joint venture entity, Zydus Sunshine Lifesciences (Private) Limited, will see both partners hold equal stakes, with Zydus subscribing to 50% of the total paid-up equity share capital. The project involves an investment commitment of over USD 20 million to develop a state-of-the-art facility in the Board of Investment zone in Horana.

The Share Subscription and Shareholders’ Agreement was signed on June 26, 2026. Zydus Lifesciences will subscribe to the shares through a cash consideration of up to USD 5 million in one or more tranches, subject to specific adjustments. The subscription is expected to be completed within 90 working days from the date of execution of the agreement. The target entity, incorporated on May 30, 2026, currently has nil turnover as it is a recently established company.

Joint Venture Structure and Governance

The Board of Zydus Sunshine Lifesciences will comprise six directors, with three representatives each from Zydus Lifesciences and Sunshine Healthcare Lanka. Zydus will appoint the Chairperson, who will hold a casting vote on all matters except reserved matters. Any changes to the capital structure will require the approval of both partners. The transaction does not fall within related party transactions, and none of the promoter or group companies have any interest in the subscription.

The facility will be developed on nearly four acres of land in the Horana Export Processing Zone. It will focus on manufacturing pharmaceutical products for Sri Lanka's retail market. The project is designed to support national supply chain resilience and enhance the availability of essential medicines under the oversight of the Board of Investment of Sri Lanka, with the Ministry of Health and the National Medicines Regulatory Authority as key stakeholders.

Particulars Details
Name of Target Entity Zydus Sunshine Lifesciences (Private) Limited
Date of Incorporation May 30, 2026
Shareholding Acquired 50%
Cost of Acquisition Up to USD 5 million
Total Investment Commitment Over USD 20 million
Location Horana Export Processing Zone, Sri Lanka
Industry Pharmaceuticals

Historical Stock Returns for Zydus Life Science

1 Day5 Days1 Month6 Months1 Year5 Years
-0.26%+0.51%+6.05%+32.92%+19.25%+80.24%

What is the projected timeline for the facility to become fully operational and begin commercial production?

Which specific therapeutic segments or essential medicines will be prioritized for manufacturing at the new facility?

How will this joint venture impact Zydus Lifesciences' revenue contribution from international markets over the next fiscal year?

Zydus extinguishes 87.3 lakh shares bought back at ₹1,260

2 min read     Updated on 21 Jun 2026, 02:08 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Zydus Lifesciences extinguished 87,30,158 equity shares bought back at ₹1,260 per share, reducing its equity capital to 99,75,03,832 shares. The buyback, fully subscribed and capped at ₹1,100 crore, increased promoter holding to 75.01%.

powered bylight_fuzz_icon
43310324

*this image is generated using AI for illustrative purposes only.

Zydus Lifesciences Limited has extinguished 87,30,158 equity shares bought back at a price of ₹1,260 per share, reducing its issued, subscribed, and fully paid-up share capital to 99,75,03,832 equity shares. The extinguishment was completed on June 18, 2026, in compliance with Regulation 11 of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018. The buyback, which was fully subscribed, utilized an aggregate amount not exceeding ₹1,100 crore. Following the extinguishment, the company disclosed the acceptance of shares tendered by promoters and key managerial personnel under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Share Capital Reconciliation

The reconciliation of the share capital confirms the reduction following the extinguishment process. The company bought back the shares through a tender offer that opened on June 4, 2026, and closed on June 10, 2026.

Particulars No. of Equity Shares Amount (in ₹)
Pre-extinguishment: Issued, Subscribed and Fully Paid-Up Share Capital 100,62,33,990 100,62,33,990
Less: Equity Shares bought back (Electronic Form) 87,30,158 87,30,158
Post-extinguishment: Issued, Subscribed and Fully Paid-Up Share Capital 99,75,03,832 99,75,03,832

Shareholding Pattern

The post-buyback shareholding pattern indicates a shift in promoter holding. Promoter and Promoter Group holding increased to 75.01% of the post-buyback equity share capital, up from 74.99% prior to the buyback.

Category of Shareholder No. of Shares Pre-Buyback % Pre-Buyback No. of Shares Post-Buyback % Post-Buyback
Promoter and Promoter Group 75,46,25,314 74.99 74,82,73,673 75.01
Non Promoters 25,16,08,676 25.01 24,92,30,159 24.99
Total 100,62,33,990 100.00 99,75,03,832 100.00

Insider Trading Disclosures

Disclosures filed under SEBI (Prohibition of Insider Trading) Regulations, 2015, detailed the acceptance of shares by promoters, directors, and their relatives. Zydus Family Trust, a promoter entity, tendered 63,49,542 shares, while Pankajbhai Ramanbhai Patel, Promoter and Director, had 124 shares accepted. Sharvil Pankajbhai Patel, Promoter and Managing Director, saw 124 shares accepted. Tushar Dhansukh Shroff, Chief Financial Officer, had 5 shares accepted.

Regulatory Compliance

National Securities Depository Limited confirmed the extinguishment of the shares in dematerialized form on June 18, 2026. A certificate of extinguishment dated June 19, 2026, was issued by the company's Chairman, Managing Director, and Company Secretary, confirming compliance with the Buyback Regulations. The company submitted the public announcement regarding the extinguishment to the exchanges on June 19, 2026.

Historical Stock Returns for Zydus Life Science

1 Day5 Days1 Month6 Months1 Year5 Years
-0.26%+0.51%+6.05%+32.92%+19.25%+80.24%

How will the reduction in equity shares impact Zydus Lifesciences' earnings per share (EPS) and future dividend payouts?

What strategic capital allocation plans does Zydus Lifesciences intend to pursue following the completion of this ₹1,100 crore buyback?

Will the slight increase in promoter holding to 75.01% lead to any changes in corporate governance or strategic decision-making?

More News on Zydus Life Science

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:+19.25%